Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday 26, 2026. Deta ...
Zacks Investment Research on MSN
Is most-watched stock Novavax, Inc. (NVAX) worth betting on now?
Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
StockStory.org on MSN
Amphastar Pharmaceuticals, Novavax, and Organon shares skyrocket, what you need to know
What Happened? A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes ...
The FDA has issued a long-awaited approval of Novavax's COVID-19 vaccine (Nuvaxovid), but with unusual restrictions. Novavax makes the nation's only traditional protein-based coronavirus vaccine -- ...
Context for Novavax after recent share performance Novavax (NVAX) has drawn fresh attention after a recent move in its share price, with the stock showing a 3.3% one day return alongside gains over ...
A medical worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax at the Tegel vaccination center on February 28, 2022 in Berlin, Germany. This story was originally published on ...
Ampoules of Novavax's COVID-19 vaccine prepared in Berlin, Germany. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
Following its emergency authorization last month, just 7,300 doses of Novavax's COVID-19 vaccine have been administered to Americans across the country, newly updated data from the Centers for Disease ...
Gaithersburg-based Novavax said Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, and ...
WASHINGTON — The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is sowing uncertainty ...
Under the non-exclusive agreement, Pfizer will utilize Novavax’s Matrix-M adjuvant in products across two disease areas, with Novavax receiving a $30 million upfront payment. Additionally, the ...
WASHINGTON — The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions. Novavax makes the nation’s only traditional protein-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results